Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: Data from the Heart and Soul Study

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 587-592

  Beatty, Alexis L ^a   Zhang, Mary H ^b   Ku, Ivy A ^a,c   Na, Beeya ^d   Schiller, Nelson B ^a   Whooley, Mary A ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c KAISER PERMANENTE   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adiponectin; Ischemic heart disease; Outcomes; Reverse epidemiology

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DEATH; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STRESS ECHOCARDIOGRAPHY;

ADIPONECTIN; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY, STRESS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SAN FRANCISCO; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; UP-REGULATION;

EID: 84855971336     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.038     Document Type: Article

References (30)

1. Ouchi N., Shibata R., Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med 2006, 16:141-146.
2. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
3. Yamamoto Y., Hirose H., Saito I., et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002, 103:137-142.
4. Adamczak M., Wiecek A., Funahashi T., et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003, 16:72-75.
5. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
6. Ai M., Otokozawa S., Asztalos B.F., et al. Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis 2011, 217:543-548.
7. Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007, 92:571-576.
8. Lawlor D.A., Davey Smith G., Ebrahim S., et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005, 90:5677-5683.
9. Kanaya A.M, Wassel Fyr C., Vittinghoff E., et al. Serum adiponectin and coronary heart disease risk in older Black and White Americans. J Clin Endocrinol Metab 2006, 91:5044-5050.
10. Wannamethee S.G., Whincup P.H., Lennon L., et al. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007, 167:1510-1517.
11. Zhang M.H., Spies C., Ali S., et al. Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. Atherosclerosis 2009, 205:233-238.
12. Wilson S.R., Sabatine M.S., Wiviott S.D., et al. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J 2011, 161:1147-1155. e1141.
13. Whooley M.A., de Jonge P., Vittinghoff E., et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008, 300:2379-2388.
14. Luepker R.V. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee, World Heart Federation Council on Epidemiology and Prevention, the European Society of Cardiology Working group on Epidemiology and Prevention, Centers for Disease Control and Prevention, and the National Heart, Lung, and Blood Institute. Circulation 2003, 108:2543-2549.
15. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147.
16. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
17. Dekker J.M., Funahashi T., Nijpels G., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008, 93:1489-1496.
18. Cavusoglu E., Ruwende C., Chopra V., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006, 27:2300-2309.
19. Maiolino G., Cesari M., Sticchi D., et al. Plasma adiponectin for prediction of cardiovascular events and mortality in high-risk patients. J Clin Endocrinol Metab 2008, 93:3333-3340.
20. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762.
21. Rathmann W., Herder C. Adiponectin and cardiovascular mortality: evidence for " reverse epidemiology" Horm Metab Res 2007, 39:1-2.
22. Dahabreh I.J., Kent D.M. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 2011, 305:822-823.
23. Kalantar-Zadeh K., Block G., Horwich T., et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004, 43:1439-1444.
24. Soydinc S., Davutoglu V., Sari I. High serum levels of adiponectin improve coronary collateral development in patients with coronary artery disease. Tohoku J Exp Med 2007, 211:347-352.
25. Takano H., Obata J.E., Kodama Y., et al. Adiponectin is released from the heart in patients with heart failure. Int J Cardiol 2009, 132:221-226.
26. Tsukamoto O., Fujita M., Kato M., et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009, 53:2070-2077.
27. Kintscher U. Does adiponectin resistance exist in chronic heart failure?. Eur Heart J 2007, 28:1676-1677.
28. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
29. Van Berendoncks A.M., Garnier A., Beckers P., et al. Exercise training reverses adiponectin resistance in skeletal muscle of patients with chronic heart failure. Heart 2011, 97:1403-1409.
30. von Eynatten M., Humpert P.M., Bluemm A., et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 2008, 199:123-128.